Education and Training
Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate.
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: Telotristat etiprate
Eligibility
Inclusion Criteria:
- Ongoing participation in a Phase 2 [LX1606.1-202-CS (NCT00853047), LX1606.1-203-CS
(NCT01104415)] or Phase 3 [LX1606.1-301-CS (NCT01677910), LX1606.1-303-CS
(NCT02063659)] study
- Patients of childbearing potential must agree to use an adequate method of
contraception (defined as having a failure rate of <1% per year) during the study and
for 12 weeks after the Follow-up visit.
- Ability and willingness to provide written informed consent
Exclusion Criteria:
- Major protocol violations or tolerability concerns in a Phase 2 (eg, LX1606.1-202-CS,
LX1606.1-203-CS) or Phase 3 (eg, LX1606.1-301-CS, LX1606.1-303-CS) study
- Positive pregnancy test
- Presence of any clinically significant findings at entry for medical history,
laboratory values, or physical examination
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061
Not Recruiting